SYRS
Syros Pharmaceuticals, Inc.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Neutral
0/100
Last price
0.00
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.00
Day high
0.00
Day low
0.00
Volume
904
Market cap
$10.73K
P/E (TTM)
—
52W range
0.00 – 0.02
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
0.00%
-1.2%
3M
+300.00%
+295.5%
6M
+100.00%
+81.8%
YTD
+14.29%
+0.0%
1Y
-92.00%
-108.4%
3Y
-99.99%
-182.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SYRS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 2, 24 | SIMONIAN NANCY A Director |
SELL | 37.07K | $10.02K | Direct |
| Nov 25, 24 | SIMONIAN NANCY A Director |
SELL | 134.71K | $35.74K | Direct |
| Nov 19, 24 | QUIRK GERALD E. Officer |
SELL | 46.66K | $12.91K | Direct |
| Nov 18, 24 | ROTH DAVID A M.D. Officer |
SELL | 12.10K | $2.38K | Direct |
| Nov 18, 24 | STEPHENS KRISTIN Officer |
SELL | 36.13K | $7.95K | Direct |
| Nov 18, 24 | CHEE CONLEY Chief Executive Officer |
SELL | 134.80K | $26.93K | Direct |
| Nov 18, 24 | HAAS JASON Chief Financial Officer |
SELL | 137.80K | $28.98K | Direct |
| Oct 31, 24 | SIMONIAN NANCY A Director |
— | 40.13K | — | Direct |
| Oct 31, 24 | ROTH DAVID A M.D. Officer |
— | 18.88K | — | Direct |
| Oct 31, 24 | STEPHENS KRISTIN Officer |
— | 17.00K | — | Direct |
| Oct 31, 24 | CHEE CONLEY Chief Executive Officer |
— | 17.00K | — | Direct |
| Oct 31, 24 | HAAS JASON Chief Financial Officer |
— | 18.88K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHEE CONLEY |
Chief Executive Officer | 0 | Sale |
HAAS JASON |
Chief Financial Officer | 0 | Sale |
QUIRK GERALD E. |
Officer | 0 | Sale |
ROTH DAVID A M.D. |
Officer | 0 | Sale |
SIMONIAN NANCY A |
Director | 4.00K | Sale |
STEPHENS KRISTIN |
Officer | 0 | Sale |
Fundamentals
Market cap$10.73K
Enterprise value$1.96M
Revenue (TTM)$386.00K
Gross profit$-88.25M
EBITDA$-110.18M
Net income$-97.81M
EPS (TTM)$-6.14
Free cash flow$-57.94M
Total cash$58.27M
Total debt$60.23M
Book value / share$-0.42
Shares outstanding26.83M
Float26.83M
Short % of float17.01%
Dividend yield0.00%
Beta (5Y)1.69
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.00
PEG ratio—
Price / sales—
Price / book—
EV / revenue5.08
EV / EBITDA-0.02
Gross margin0.00%
Operating margin-28891.71%
Profit margin0.00%
Return on equity-776.96%
Return on assets-59.88%
Debt / equity—
Current ratio2.25
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|
| Total revenue | $9.94M | $14.88M | $23.49M | -33.2% |
| Operating revenue | $9.94M | $14.88M | $23.49M | -33.2% |
| Research & development | $108.15M | $111.94M | $99.87M | -3.4% |
| Selling, general & admin | $28.28M | $29.30M | $23.04M | -3.5% |
| Total operating expense | $136.44M | $141.24M | $122.91M | -3.4% |
| Operating income | -$126.50M | -$126.36M | -$99.42M | -0.1% |
| Net interest income | $1.69M | -$2.00M | -$3.82M | +184.4% |
| Pre-tax income | -$164.57M | -$94.65M | -$86.56M | -73.9% |
| Net income | -$164.57M | -$94.65M | -$86.56M | -73.9% |
| Net income to common | -$164.57M | -$94.65M | -$86.56M | -73.9% |
| Basic EPS | -5.81 | -7.49 | -13.84 | +22.4% |
| Diluted EPS | -5.81 | -7.49 | -13.84 | +22.4% |
| EBIT | -$159.45M | -$90.52M | -$82.65M | -76.1% |
| EBITDA | -$157.19M | -$87.81M | -$79.63M | -79.0% |
| Basic shares | 28.33M | 12.63M | 6.25M | +124.2% |
| Diluted shares | 28.33M | 12.63M | 6.25M | +124.2% |
| Line item | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $139.53M | $167.47M | $92.30M | -16.7% |
| Cash & short-term investments | $139.53M | $202.30M | $130.37M | -31.0% |
| Accounts receivable | — | — | $0 | — |
| Total current assets | $144.98M | $211.39M | $136.59M | -31.4% |
| Property, plant & equipment | $19.48M | $24.66M | $27.29M | -21.0% |
| Total assets | $168.17M | $244.49M | $182.94M | -31.2% |
| Total current liabilities | $36.68M | $30.78M | $31.51M | +19.2% |
| Current debt | $6.67M | — | — | — |
| Long-term debt | $34.56M | $40.65M | $40.26M | -15.0% |
| Total debt | $62.08M | $63.57M | $65.19M | -2.4% |
| Total liabilities | $151.51M | $116.75M | $97.72M | +29.8% |
| Retained earnings | -$722.81M | -$558.23M | -$463.58M | -29.5% |
| Shareholder equity | $16.66M | $127.74M | $85.22M | -87.0% |
| Working capital | $108.30M | $180.61M | $105.08M | -40.0% |
| Net tangible assets | $16.66M | $127.74M | $85.22M | -87.0% |
| Shares issued | 26.45M | 20.26M | 6.20M | +30.5% |
| Line item | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|
| Net income | -$164.57M | -$94.65M | -$86.56M | -73.9% |
| Depreciation & amortisation | $2.25M | $2.71M | $3.02M | -16.8% |
| Stock-based compensation | $10.43M | $11.41M | $10.35M | -8.6% |
| Change in working capital | $5.05M | -$5.52M | -$10.60M | +191.6% |
| Operating cash flow | -$109.71M | -$123.06M | -$99.54M | +10.9% |
| Capital expenditure | -$272.00K | -$1.24M | -$1.25M | +78.1% |
| Investing cash flow | $37.34M | $67.19M | -$52.65M | -44.4% |
| Share buybacks | $0 | -$81.00K | — | +100.0% |
| Financing cash flow | $43.46M | $131.04M | $70.51M | -66.8% |
| Free cash flow | -$109.98M | -$124.31M | -$100.78M | +11.5% |
| End cash position | $141.65M | $170.55M | $95.39M | -16.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Sep 2024 | -0.67 | -0.16 | +76.0% |
| Jun 2024 | -0.77 | -0.59 | +22.9% |
| Mar 2024 | -0.94 | -0.10 | +89.3% |
| Dec 2023 | -1.12 | -2.22 | -98.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | -0.71 | 3 | $0 | — |
| Current year | — | — | $0 | — |
| Next year | -2.61 | 4 | $0 | — |
Analyst targets & ownership
Mean target$8.75
High target$20.00
Low target$4.00
Implied upside2187400.00%
Analyst count4
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.00%
Institutions holding0
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.00
+0.00% from price
SMA 20
0.00
-59.18% from price
SMA 50
0.00
-23.95% from price
SMA 100
0.00
+15.11% from price
SMA 200
0.00
+17.99% from price
EMA 12
0.00
-29.69% from price
EMA 26
0.00
-39.43% from price
EMA 50
0.00
-30.80% from price
RSI (14)
48.4
Neutral
MACD (12,26,9)
-0.00
Hist -0.00
ATR (14)
0.00
207.14% of price
Realised vol 30D
1449.0%
Annualised
Bollinger upper
0.01
20, 2σ
Bollinger lower
-0.00
20, 2σ
50 / 200 cross
Golden
0.00 vs 0.00
Trend bias
Above 200
+17.99%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-12.92
Less volatile than market
Correlation to SPY
-0.05
Largely independent
Realised vol 30D
1449.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-98.0%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.00
207.14% of price
Beta (reported)
1.69
5Y monthly, from filing
Short interest
Shares short
4.19M
Prior 913.09K
Change vs prior
+359.4%
Shorts adding
% of float
17.01%
Elevated
% of shares out
15.63%
Against total outstanding
Days to cover
0.1
Liquid
Float
26.83M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 24 | TD Cowen | DOWNGRADE | Buy | Hold |
| Nov 13, 24 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Nov 13, 24 | JMP Securities | DOWNGRADE | Market Outperform | Market Perform |
| Nov 13, 24 | Brookline Capital | DOWNGRADE | Buy | Hold |
| Nov 1, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 13, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 13, 24 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Aug 13, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 1, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 26, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 3, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateSep 19, 2022
SEC filings
Notice of termination of registration of a class of securities under Section 12(g)
15-12G · 2025-03-20
Post-effective amendment to a registration statement that is not immediately effective upon filing
POS AM · 2025-03-10
Corporate Changes & Voting Matters
8-K · 2025-03-04
Corporate Changes & Voting Matters
8-K · 2025-02-28
Corporate Changes & Voting Matters
8-K · 2025-01-08
Corporate Changes & Voting Matters
8-K · 2024-12-06
Corporate Changes & Voting Matters
8-K · 2024-11-18
Corporate Changes & Voting Matters
8-K · 2024-11-13
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.